The COVID-19 pandemic has affected many sectors across the country, including the eye care community. To address this, Alcon has created a new support program to help eye care practices rebound by meeting the treatment needs of patients with dry eye disease. The program, “No Reason to Wait: Success Starts Now” aims to help practitioners realize the earning potential of treating Meibomian Gland Dysfunction in their practice.
“The COVID-19 crisis created a backlog of dry eye patients who might be looking for treatment of Meibomian Gland Dysfunction (MGD), the root cause of their evaporative dry eye disease. This presents a unique opportunity for eye care practitioners looking to bring more value to each patient coming through their doors,” said Adam Szaronos, Head, U.S. Dry Eye Devices, Alcon.
The program will launch with an array of resources for optometrists and ophthalmologists interested in enhancing their practices by adopting the Systane iLux Suite to generate cash flow with elective procedures. These include the Systane iLux system, DEEP™ (Dry Eye Excellence Program), and the Systane® MyEyes Program. There will also be a series of web events focused on everything from virtual demos and practice protocols to sessions with leading dry eye thought leaders discussing the most common implementation barriers and forthcoming learning modules on Alcon Experience Academy.
In addition, Alcon recently received clearance from the U.S. FDA to market the new Systane®iLux2® which will combine: high-resolution digital visualization, recording and media storage; a built-in near infrared meibography camera; and, white light surface imaging into a single, handheld, portable device. Practitioners who join the “No Reason to Wait” program by purchasing a Systane iLux will have exclusive access to upgrade to the Systane iLux2 at preferred pricing once it becomes available in late 2021.
“The ‘No Reason to Wait’ program brings together leading MGD technology, a proven implementation program, and a newly launched platform for driving long-term patient compliance and retention for practices offering procedures with the Systane iLux system. The program will help eye doctors deliver effective solutions to more patients, create new avenues of revenue at a time of critical need, and address barriers that might prevent successful practice entry and adoption of MGD procedures.”
Full news release: https://www.alcon.com/media-release/new-alcon-program-helps-eye-care-professionals-tap-opportunities-dry-eye-market-amid